Lymphocyte development from murine hematopoietic stem cells (HSCs) entails a loss of self-renewal capacity and a progressive restriction of developmental potential. Previous research from our laboratory suggests that specialized assemblies of ATP-dependent SWI/SNF chromatin-remodeling complexes play lineage-specific roles during murine hematopoiesis. Here, we demonstrate that the Smarcd1 subunit is essential for specification of lymphoid cell fate from multipotent progenitors. Acute deletion of Smarcd1 in murine adult hematopoiesis leads to lymphopenia, characterized by a near-complete absence of early lymphoid progenitors and mature B and T cells, while the myeloid and erythroid lineages remain unaffected. Mechanistically, we demonstrate that Smarcd1 is essential for the coordinated activation of a lymphoid gene signature in murine multipotent progenitors. This is achieved by interacting with the E2a transcription factor at proximal promoters and by regulating the activity of distal enhancers. Globally, these findings identify Smarcd1 as an essential chromatin remodeler that governs lymphoid cell fate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.devcel.2024.08.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ARID1A is a coactivator of STAT5 that contributes to CD8 T cell dysfunction and anti-PD-1 resistance in gastric cancer.
Pharmacol Res
December 2024
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China. Electronic address:
ARID1A deletion mutation contributes to improved treatment of several malignancies with immune checkpoint inhibitors (ICIs). However, its role in modulating of tumor immune microenvironment (TIME) of gastric cancer (GC) remains unclear. Here, we report an increase of CD8 T cells infiltration in GC patients with ARID1A-mutation (MUT), which enhances sensitivity to ICIs.
View Article and Find Full Text PDFLow SMARCD3 expression is associated with poor prognosis in patients with prostate cancer.
Prostate
February 2025
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Article Synopsis
- SWI/SNF complexes are multi-subunit chromatin remodelers linked to disruptions in over 20% of human tumors, with specific attention given to the SMARCD family in prostate cancer.
- A study using immunohistochemistry on tissue samples found that SMARCD1 and SMARCD3 protein levels were significantly higher in tumor tissues compared to benign tissues, particularly in lymph node metastases.
- While SMARCD1 did not correlate with clinical outcomes, low SMARCD3 levels were associated with increased progression to metastasis, suggesting potential roles as biomarkers in prostate tumorigenesis.
Smarcd1 subunit of SWI/SNF chromatin-remodeling complexes collaborates with E2a to promote murine lymphoid specification.
Dev Cell
December 2024
Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada; Department of Pathology and Cellular Biology, Faculty of Medicine, University of Montreal, Montreal, QC H3T 1J4, Canada. Electronic address:
Lymphocyte development from murine hematopoietic stem cells (HSCs) entails a loss of self-renewal capacity and a progressive restriction of developmental potential. Previous research from our laboratory suggests that specialized assemblies of ATP-dependent SWI/SNF chromatin-remodeling complexes play lineage-specific roles during murine hematopoiesis. Here, we demonstrate that the Smarcd1 subunit is essential for specification of lymphoid cell fate from multipotent progenitors.
View Article and Find Full Text PDFPan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Clin Transl Med
February 2024
Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Background: Mutations in one or more genes responsible for encoding subunits within the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodelling complexes are found in approximately 25% of cancer patients. Bromodomain containing 9 (BRD9) is a more recently identified protein coding gene, which can encode SWI/SNF chromatin-remodelling complexes subunits. Although initial evaluations of the potential of BRD9-based targeted therapy have been explored in the clinical application of a small number of cancer types, more detailed study of the diagnostic and prognostic potential, as well as the detailed biological mechanism of BRD9 remains unreported.
View Article and Find Full Text PDFThe SMARCD Family of SWI/SNF Accessory Proteins Is Involved in the Transcriptional Regulation of Androgen Receptor-Driven Genes and Plays a Role in Various Essential Processes of Prostate Cancer.
Cells
December 2022
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Article Synopsis
- Previous studies indicate that SWI/SNF complexes, involved in chromatin remodeling, have both tumor-suppressing and oncogenic roles in prostate cancer.
- The SMARCD family members (BAF60A, BAF60B, BAF60C) are key components that regulate androgen receptor-driven genes and play a role in the progression to castration-resistant prostate cancer.
- The findings highlight the complex functions of SMARCD proteins in prostate carcinogenesis, emphasizing their dual roles and the need to consider these interactions in developing targeted therapies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!